利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.029 秒)

    Binding agents which inhibit myostatin
    2.
    发明授权
    Binding agents which inhibit myostatin 有权
    抑制肌生成抑制素的结合剂

    公开(公告)号：US07928075B2

    公开(公告)日：2011-04-19

    申请号：US12322977

    申请日：2009-02-10

    申请人： Hq Han ,  Hosung Min ,  Thomas C. Boone

    发明人： Hq Han ,  Hosung Min ,  Thomas C. Boone

    IPC分类号： A61K38/04 ,  A61K38/10 ,  A61K38/16 ,  C07K7/00 ,  C07K14/00

    CPC分类号： C07K16/22 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/475 ,  C07K2317/21 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/35 ,  C12N2710/14143 ,  G01N33/567 ,  G01N33/74 ,  G01N2333/475

    摘要： The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

    摘要翻译： 本发明提供了包含能够结合肌生成抑制素并抑制其活性的肽的结合剂。 在一个实施方案中，结合剂包含至少一种与至少一种载体如聚合物或Fc结构域直接或间接连接的肌肉生长抑制素结合肽。 本发明的粘合剂在施用于动物时产生瘦肌肉质量的降低，并且脂肪与肌肉的比例降低。 含有本发明结合剂的治疗组合物可用于治疗肌肉消瘦疾病和代谢紊乱，包括糖尿病和肥胖症。

    NOVEL BIFUNCTIONAL MULTISPECIFIC ANTAGONISTS CAPABLE OF INHIBITING MULTIPLE LIGANDS OF TGF-BETA FAMILY AND USES THEREOF
    4.
    发明公开
    NOVEL BIFUNCTIONAL MULTISPECIFIC ANTAGONISTS CAPABLE OF INHIBITING MULTIPLE LIGANDS OF TGF-BETA FAMILY AND USES THEREOF 审中-公开

    公开(公告)号：US20240343788A1

    公开(公告)日：2024-10-17

    申请号：US18034499

    申请日：2021-10-29

    申请人： HQ Han ,  Xiaolan Zhou

    发明人： HQ Han ,  Xiaolan Zhou

    IPC分类号： C07K16/22 ,  A61K39/00 ,  C07K16/28

    CPC分类号： C07K16/22 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/76

    摘要： This invention disclosure describes novel polypeptide antagonists capable of neutralizing multiple members of TGF-β family in a selective manner. Specifically, the multispecific polypeptide antagonists disclosed herein comprise at least one Activin-binding domain and at least one TGF-β-binding domain and therefore, are capable of neutralizing TGF-β and Activin as well as Activin-related ligands in parallel. Moreover, this invention disclosure also discloses bifunctional multispecific polypeptide antagonists designed to inhibit Activin, TGF-β and T-Cell immune checkpoint (i.e., PD1, PDL1 or CTLA4) in a simultaneous manner. Specifically, the bifunctional multispecific antagonists disclosed herein comprise at least one Activin-binding domain, at least one TGF-β-binding domain and at least one PD1-, PDL1- or CTLA4-binding domain. Also provided are pharmaceutical compositions of such multispecific or bifunctional multispecific polypeptide antagonists and their therapeutic uses for treating certain disease conditions, which involve overexpression of both TGF-β and Activin, such as fibrosis and cancer.

    BIFUNCTIONAL ANTAGONISTS OF ACTIVIN/TGF-BETA AND RANKL AND USES THEREOF
    9.
    发明公开
    BIFUNCTIONAL ANTAGONISTS OF ACTIVIN/TGF-BETA AND RANKL AND USES THEREOF 审中-公开

    公开(公告)号：US20230391880A1

    公开(公告)日：2023-12-07

    申请号：US18034708

    申请日：2021-11-05

    申请人： HQ Han ,  Xiaolan Zhou

    发明人： HQ Han ,  Xiaolan Zhou

    IPC分类号： C07K16/28 ,  C07K16/22 ,  C07K14/71

    CPC分类号： C07K16/2875 ,  C07K16/22 ,  C07K14/71 ,  A61K2039/505

    摘要： This invention disclosure provides novel bifunctional molecules comprising at least one RANKL binding molecule and at least one Activin or TGF-β binding molecule, which are capable of sequestering RANKL and Activin or TGF-β in parallel. Also provided are pharmaceutical compositions of such bifunctional antagonist molecules and their therapeutic uses to treat various bone disorders whose pathogenesis involves the activation of both RANKL-NFκB and Activin/TGFβ-Smad2/3 signaling pathways, such as bone metastasis, bone loss in cancer, bone fragility in neuromuscular diseases, osteogenesis imperfecta, fracture, osteopenia and osteoporosis.

    Method of increasing muscle mass by administering a myostatin binding agent
    10.
    发明授权
    Method of increasing muscle mass by administering a myostatin binding agent 有权
    通过施用肌肉生长抑制素结合剂来增加肌肉质量的方法

    公开(公告)号：US08071538B2

    公开(公告)日：2011-12-06

    申请号：US12806880

    申请日：2010-08-23

    申请人： Hq Han ,  Hosung Min ,  Thomas C. Boone

    发明人： Hq Han ,  Hosung Min ,  Thomas C. Boone

    IPC分类号： A61K38/00 ,  A61K38/04 ,  A61K38/08

    CPC分类号： C07K16/22 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/00 ,  C07K14/475 ,  C07K2317/21 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/35 ,  C12N2710/14143 ,  G01N33/567 ,  G01N33/74 ,  G01N2333/475

    摘要： The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.

    摘要翻译： 本发明提供了包含能够结合肌生成抑制素并抑制其活性的肽的结合剂。 在一个实施方案中，结合剂包含至少一种与至少一种载体如聚合物或Fc结构域直接或间接连接的肌肉生长抑制素结合肽。 本发明的粘合剂在施用于动物时产生瘦肌肉质量的降低，并且脂肪与肌肉的比例降低。 含有本发明结合剂的治疗组合物可用于治疗肌肉消瘦疾病和代谢紊乱，包括糖尿病和肥胖症。